AbbVie Reports Strong Q2 2026 Results: Robust Growth, Major Acquisition, and Pipeline Progress
AbbVie Inc. (NYSE: ABBV) has reported impressive financial results for the second quarter of 2026, underpinned by double-digit revenue growth, significant pipeline advancements, and the announcement of a transformative acquisition. These developments are highly relevant to shareholders and may impact the company’s share price.
Key Financial Highlights
- Q2 2026 Diluted EPS: \$2.03 on a GAAP basis (up 290.4% year-on-year), and \$3.65 on an adjusted basis (up 22.9%). Results include a \$0.17 per share negative impact from acquired IPR&D and milestone expenses.
- Net Revenues: \$16.990 billion, reflecting a 10.2% increase on a reported basis and 9.5% on an operational basis.
-
Strong Segment Growth:
- Immunology: \$8.786 billion (up 15.1% reported, 14.6% operational), driven by Skyrizi (\$5.505 billion, +24.4%) and Rinvoq (\$2.525 billion, +24.5%). Humira declined to \$756 million (-35.9%) as biosimilar competition intensifies.
- Neuroscience: \$3.228 billion (up 20.3%), led by Vraylar (\$1.071 billion, +18.9%) and Botox Therapeutic (\$1.042 billion, +12.2%). Ubrelvy (\$392 million, +16%), Qulipta (\$350 million, +30.9%), and Vyalev (\$256 million) also contributed.
- Oncology: \$1.650 billion (down 1.5%), with Venclexta (\$771 million, +11.6%) partially offsetting declines in Imbruvica (\$532 million, -29.4%). Elahere revenues surged to \$211 million (+33.1%).
- Aesthetics: \$1.282 billion (up 0.3%), with Botox Cosmetic (\$728 million, +5.2%) offsetting a 6% decline in Juvederm (\$245 million).
- Margins and Expenses: Adjusted gross margin was 84.7%. Adjusted operating margin reached 48.3%. Adjusted SG&A was 21.0% of net revenues and adjusted R&D was 13.6%.
- Net Interest Expense: \$679 million.
- Adjusted Tax Rate: 14.7% for Q2.
Strategic and Price-Sensitive Developments
1. Major Acquisition: Apogee Therapeutics
- AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately \$10.9 billion. Apogee’s pipeline focuses on immunology, including zumilokibart (APG777) for atopic dermatitis and APG273 for asthma.
- The deal is expected to close in Q3 2026. The acquisition is projected to be \$0.14 dilutive to 2026 adjusted EPS but brings substantial long-term value and strengthens AbbVie’s immunology leadership.
2. Updated 2026 Guidance
- AbbVie revised its full-year 2026 adjusted diluted EPS guidance to \$13.87 – \$14.07 (down \$0.04 at the midpoint), reflecting the Apogee acquisition dilution, partially offset by operational overperformance.
- The guidance includes a \$0.58 per share negative impact from acquired IPR&D and milestone expenses year-to-date, but excludes any future IPR&D/milestone impacts beyond Q2, as those are unpredictable.
3. Regulatory and Pipeline Advancements
- Skyrizi: Approved by FDA and European Commission for pediatric psoriasis and psoriatic arthritis. Supported by positive Phase 3 data.
- Rinvoq: Received EU approval for non-segmental vitiligo and severe alopecia areata, both first-in-class systemic options.
- Qulipta (Aquipta): EU approval for acute migraine in adults, now approved for both acute and preventive migraine treatment.
- Decnupaz (pivekimab sunirine): FDA approved for BPDCN, marking AbbVie’s first antibody-drug conjugate for blood cancer.
- Venclexta (venetoclax): EU label expansion for all-oral, fixed-duration regimens in CLL.
- Tepkinly (epcoritamab): EU approval in relapsed/refractory follicular lymphoma (R/R FL) as the first bispecific-based therapy approved in Europe for this setting.
- Epkinly (epcoritamab): Positive Phase 3 results in R/R DLBCL; combination with lenalidomide showed significant PFS improvement.
- Maviret: EU approval for acute hepatitis C in adults/children, now the only treatment approved for both acute and chronic HCV in EU.
- Allergan Aesthetics: New FDA approval for Skinvive by Juvederm for neck lines; Boey (trenibotulinumtoxinE) approved in EU and Canada for rapid-onset glabellar lines.
Conference Call and Further Information
AbbVie will host an investor conference call at 8:00 a.m. Central Time to discuss these results and outlook. Investors can access the webcast and archived call via AbbVie’s investor relations site.
Potential Share Price Implications
- The robust double-digit growth in immunology and neuroscience, the Apogee Therapeutics acquisition, and continuous pipeline progress are likely to be viewed positively by investors, reinforcing AbbVie’s long-term growth outlook.
- The dilution to 2026 EPS guidance from the Apogee acquisition is small and partially offset, but the potential for Apogee’s assets to deliver “mega-blockbuster” sales could drive future valuation upside.
- Regulatory wins and label expansions across multiple products de-risk future revenue streams and demonstrate pipeline productivity, which are essential for offsetting Humira biosimilar erosion.
- Investors should closely monitor the integration and performance of Apogee’s pipeline, as well as any additional IPR&D/milestone expenses which may impact future EPS.
Risks and Forward-Looking Statements
AbbVie cautions that forward-looking statements are subject to various risks, including but not limited to regulatory approvals, integration risks from the Apogee acquisition, pipeline development uncertainties, and broader macroeconomic factors. For further details, investors should review the latest SEC filings.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult official AbbVie filings and their financial advisors before making investment decisions. Actual results and events may differ materially from those described due to risk factors outlined by the company.
